Home › Funds › Commodore Capital LP › TNGX
Commodore Capital LP position in TNGX
TANGO THERAPEUTICS INC · Health Care
Commodore Capital LP reported holding 2,250,000 shares of TNGX (TANGO THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$70.3M, representing 4.19% of its reported portfolio and ranking #9 among its reported holdings. Commodore Capital LP has disclosed TNGX holdings in 3 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Commodore Capital LP's TNGX position evolved
Commodore Capital LP first disclosed a stake in TNGX in Q2 2025 at 1,500,000 shares (US$7.7M). The position peaked in Q2 2026 at 2,250,000 shares, worth US$70.3M. Across 3 filings, Commodore Capital LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,250,000 shares valued at US$70.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 1.50M | $7.68M | New |
| Q3 2025 | 1.50M | $12.60M | Hold |
| Q2 2026 | 2.25M | $70.33M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TNGX and 13F data
TNGX (TANGO THERAPEUTICS INC) is a Health Care company. 85 other funds we track also report a position in TNGX — the largest reported positions include RTW INVESTMENTS, LP (US$434.5M), Farallon Capital Management (US$383.8M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$383.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TNGX
- RTW INVESTMENTS, LP 13.90M sh · $434.53M · Q2 2026
- Farallon Capital Management 12.28M sh · $383.78M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 12.28M sh · $383.78M · Q2 2026
- Boxer Capital Management, LLC 10.88M sh · $339.99M · Q2 2026
- TCG Crossover Management, LLC 9.08M sh · $283.88M · Q2 2026
- Paradigm Biocapital Advisors LP 6.36M sh · $198.74M · Q2 2026
- Siren, L.L.C. 6.18M sh · $193.17M · Q2 2026
- Deep Track Capital, LP 4.20M sh · $131.29M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.19M sh · $131.00M · Q2 2026
- Woodline Partners LP 4.00M sh · $125.06M · Q2 2026
- TRV GP IV, LLC 6.37M sh · $120.18M · Q2 2026
- PERCEPTIVE ADVISORS LLC 3.38M sh · $105.57M · Q2 2026
More on Commodore Capital LP
FAQ
How long has Commodore Capital LP held TNGX?
Commodore Capital LP has disclosed TNGX holdings in 3 of the last 5 reported quarters, going back to Q2 2025.
What is Commodore Capital LP's current position in TNGX?
As of Q2 2026, Commodore Capital LP holds 2.25M shares of TNGX (TANGO THERAPEUTICS INC), valued at $70.33M, representing 4.19% of its reported portfolio and ranking #9.
Has Commodore Capital LP been buying or selling TNGX?
In the latest 13F filing (Q2 2026), Commodore Capital LP newly opened its position in TNGX. The position peaked in Q2 2026 at 2.25M shares.
Which other funds hold TNGX?
Other major institutional holders of TNGX include RTW INVESTMENTS, LP, Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., among 85 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.